Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Elite Pharmaceuticals, Inc.
Elite enters second pilot Phase I trial of its once-daily oxycodone product
June 23rd, 2006
Elite Pharmaceuticals, Inc. (ELI) has initiated a pilot Phase I pharmacokinetic study evaluating the company's ELI-154, a once-daily oxycodone HCl. This patent-pending product is intended to deliver more consistent levels of the drug to patients who take the drug for chronic pain. Currently, there is no once-daily oxycodone on the market. This is the second study for ELI-154 and the company's second oxycodone HCl product in clinical trials. The first pilot Phase I study for this product demonstrated proof of concept. This second study will evaluate variables to optimize the formulation. Upon completion of this study, Elite intends to enter into a...
Source: Biotech Law Weekly (2006-06-23)
|
